Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2013	Jul. 29, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	iart
Entity Registrant Name	INTEGRA LIFESCIENCES HOLDINGS CORP
Entity Central Index Key	0000917520
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		37,000,208

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Total revenue, net	$ 205,547	$ 210,170	$ 402,199	$ 406,355
Costs and Expenses:
Cost of goods sold	83,068	78,274	163,336	152,949
Research and development	11,809	13,131	24,525	25,043
Selling, general and administrative	99,619	96,097	199,780	183,508
Intangible asset amortization	3,073	4,647	6,624	9,367
Total costs and expenses	197,569	192,149	394,265	370,867
Operating income	7,978	18,021	7,934	35,488
Interest income	289	415	352	793
Interest expense	(4,965)	(7,103)	(9,765)	(15,032)
Other income (expense), net	(307)	236	(1,281)	(87)
Income (loss) before income taxes	2,995	11,569	(2,760)	21,162
Income tax (benefit) expense	(445)	3,055	(2,150)	5,955
Net income (loss)	3,440	8,514	(610)	15,207
Basic net income per common share (in dollars per share)	$ 0.12	$ 0.30	$ (0.02)	$ 0.54
Diluted net income per common share (in dollars per share)	$ 0.12	$ 0.30	$ (0.02)	$ 0.53
Weighted average common shares outstanding (See Note 11):
Basic (in shares)	27,873	28,419	27,834	28,382
Diluted (in shares)	28,118	28,609	27,834	28,549
Comprehensive income (loss) (See Note 12)	$ 5,317	$ (2,730)	$ (5,217)	$ 10,911

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 98,636	$ 96,938
Trade accounts receivable, net of allowances of $9,637 and $7,221	114,749	114,916
Inventories, net	195,457	171,806
Deferred tax assets	38,120	39,100
Prepaid expenses and other current assets	30,774	30,291
Total current assets	477,736	453,051
Property, plant and equipment, net	184,537	177,898
Intangible assets, net	206,884	212,267
Goodwill	292,881	294,067
Deferred tax assets	14,988	15,957
Other assets	10,475	10,359
Total assets	1,187,501	1,163,599
Current Liabilities:
Accounts payable, trade	44,767	36,742
Deferred revenue	3,748	3,505
Accrued compensation	27,822	34,914
Accrued expenses and other current liabilities	33,002	31,768
Total current liabilities	109,339	106,929
Long-term borrowings under senior credit facility	341,875	321,875
Long-term convertible securities	201,375	197,672
Deferred tax liabilities	5,396	5,393
Other liabilities	12,927	13,955
Total liabilities	670,912	645,824
Commitments and contingencies
Stockholders’ Equity:
Preferred Stock; no par value; 15,000 authorized shares; none outstanding
Common stock; $0.01 par value; 60,000 authorized shares; 36,969 and 36,852 issued at June 30, 2013 and December 31, 2012, respectively	370	369
Additional paid-in capital	591,331	587,301
Treasury stock, at cost; 8,903 shares at June 30, 2013 and December 31, 2012	(367,121)	(367,121)
Accumulated other comprehensive (loss)	(9,404)	(4,797)
Retained earnings	301,413	302,023
Total stockholders’ equity	516,589	517,775
Total liabilities and stockholders’ equity	$ 1,187,501	$ 1,163,599

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Trade accounts receivable, allowances	$ 9,637	$ 7,221
Preferred Stock, par value (in dollars per share)
Preferred Stock, authorized shares (in shares)	15,000,000	15,000,000
Preferred Stock, outstanding (in shares)
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued (in shares)	36,969,000	36,852,000
Treasury stock, shares (in shares)	8,903,000	8,903,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
OPERATING ACTIVITIES:
Net income (loss)	$ (610)	$ 15,207
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	24,025	25,808
Deferred income tax (benefit) provision	(400)	(2,554)
Amortization of debt issuance costs	1,094	1,480
Non-cash interest expense	3,232	6,496
Payment of accreted interest	0	(30,617)
Loss on disposal of property and equipment	1,831	431
Share-based compensation	4,764	4,355
Excess tax benefits from stock-based compensation arrangements	(102)	(418)
Changes in assets and liabilities, net of business acquisitions:
Accounts receivable	(745)	2,252
Inventories	(23,966)	(2,155)
Prepaid expenses and other current assets	(624)	7,664
Other non-current assets	(368)	(876)
Accounts payable, accrued expenses and other current liabilities	2,893	7,378
Deferred revenue	278	(289)
Other non-current liabilities	(538)	432
Net cash provided by operating activities	10,764	34,594
INVESTING ACTIVITIES:
Purchases of property and equipment	(24,475)	(24,642)
Sales of property and equipment	530	0
Cash used in business acquisition, net of cash acquired	(2,830)	(2,867)
Purchases of short-term investments	0	(67,907)
Maturities of short-term investments	0	26,058
Net cash used in investing activities	(26,775)	(69,358)
FINANCING ACTIVITIES:
Borrowings under senior credit facility	20,000	155,000
Repayments under senior credit facility	0	(12,812)
Payment of liability component of convertible notes	0	(134,383)
Payment of debt issuance costs	(1,013)	0
Proceeds from exercised stock options	234	250
Excess tax benefits from stock-based compensation arrangements	102	418
Net cash provided by (used in) financing activities	19,323	8,473
Effect of exchange rate changes on cash and cash equivalents	(1,614)	953
Net change in cash and cash equivalents	1,698	(25,338)
Cash and cash equivalents at beginning of period	96,938	100,808
Cash and cash equivalents at end of period	$ 98,636	$ 75,470

BASIS OF PRESENTATION	6 Months Ended
BASIS OF PRESENTATION	Jun. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION General The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise. In the opinion of management, the June 30, 2013 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K. The December 31, 2012 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. Operating results for the three and six-month periods ended June 30, 2013 are not necessarily indicative of the results to be expected for the entire year. The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and allowances, net realizable value of inventories, valuation of intangible assets including in-process research and development, amortization periods for acquired intangible assets, discount rates and estimated projected cash flows used to value and test impairments of long-lived assets and goodwill, estimates of projected cash flows and depreciation and amortization periods for long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation, valuation of pension assets and liabilities, valuation of derivative instruments, valuation of the equity component of convertible debt instruments, valuation of contingent liabilities, the fair value of debt instruments and loss contingencies. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the current circumstances. Actual results could differ from these estimates. Certain amounts from the prior year’s financial statements have been reclassified in order to conform to the current year’s presentation. Recently Issued Accounting Standards There have been no recently issued accounting standards that have an impact on the Company's financial statements.

BUSINESS ACQUISITIONS

6 Months Ended

Jun. 30, 2013

Business Combinations [Abstract]

BUSINESS ACQUISITIONS

Tarsus Medical, Inc.

On January 24, 2013, the Company acquired all outstanding preferred and common stock of Tarsus Medical, Inc. for a total of $4.7 million consisting of $2.8 million in cash (less cash acquired) and contingent consideration with an estimated acquisition date fair value of approximately $1.6 million. The potential maximum undiscounted contingent consideration consists of the first milestone payment of up to $1.5 million and the second payment of up to $11.5 million. These payments are based on reaching certain sales of acquired products. Tarsus Medical, Inc. is a podiatry device company addressing clinical needs associated with diseases and injuries of the foot and ankle.

The following summarizes the final allocation of the purchase price based on fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Cash	$	85
Prepaid expenses	13
Intangible assets			Wtd. Avg. Life:
Technology	5,040		10 - 14 years
In-process research and development	340		Indefinite
Deferred tax asset - long term	1,334
Goodwill	116
Total assets acquired	6,928
Accounts payable and other liabilities	111
Deferred tax liability	2,152
Net assets acquired	$	4,665

Management determined the preliminary fair value of net assets acquired during the first quarter of 2013 and finalized the working capital adjustment in the second quarter of 2013. The Company accounts for the contingent consideration by recording its fair value as a liability on the date of the acquisition. The contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. Changes in fair value of contingent consideration are recognized in earnings. Accordingly, on January 24, 2013 the Company recorded $1.6 million representing the initial fair value estimate of the contingent consideration that will be earned through December 31, 2015. At June 30, 2013 there was no change in the fair value of the contingent consideration. The fair value of this liability is based on future sales projections of the Tarsus Medical product under various potential scenarios and weighting the probability of these outcomes for the period ended December 31, 2015. At the date of the acquisition, the first milestone cash flow projection was discounted using a rate of 4.3% based on an estimated after tax cost of debt; the second milestone cash flow projection was discounted using a weighted average cost of capital of 16.5%. These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement.

The goodwill recorded in connection with this acquisition is based on (i) expected cost savings, operating synergies and other benefits expected to result from the combined operations, (ii) the value of the going-concern element of Tarsus’ existing business (that is, the higher rate of return on the assembled net assets versus if the Company had acquired all of the net assets separately), and (iii) intangible assets that do not qualify for separate recognition such as Tarsus’ assembled workforce. The goodwill acquired will not be deductible for tax purposes.

The impact of the Tarsus acquisition is not material to the consolidated operating results of the Company; therefore, the pro-forma impact of the acquisition has not been presented.

INVENTORIES

6 Months Ended

Jun. 30, 2013

Inventory, Net [Abstract]

INVENTORIES

Inventories, net consisted of the following:



	June 30, 2013		December 31, 2012
	(In thousands)
Finished goods	$	118,464	$	102,401
Work-in process	44,771		39,944
Raw materials	32,222		29,461
	$	195,457	$	171,806

The finished goods inventory includes $4.6 million of capitalized medical device excise tax at June 30, 2013.

GOODWILL AND OTHER INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

The excess of the cost over the fair value of net assets of acquired businesses is recorded as goodwill. Goodwill is not subject to amortization, but is reviewed for impairment at the reporting unit level annually, or more frequently if impairment indicators arise. The Company's assessment of the recoverability of goodwill is based upon a comparison of the carrying value of goodwill with its estimated fair value. This assessment is performed annually during the third quarter and was performed most recently on July 31, 2012 resulting in no impairment. However, if future results do not meet or exceed the Company's forecasts, or if unfavorable changes occur in the weighted-average cost of capital, growth assumptions for future revenue, terminal value growth rate and/or forecasted cash flows utilized in the discounted cash flow analysis, the Company may record an impairment of this goodwill at a future date.

The Company has experienced a decline in sales relative to the previous forecasts, partially with respect to its U.S. Spine and Private Label reporting units which has recorded goodwill of $46.8 million and $8.9 million, respectively. This decline is in part attributable to the recall, as well as lower sales to customers. The Company currently believes this impact is temporary. However, in the event that sales and operating results of the U.S. Spine and Private Label reporting units in the second half of the year continue to deteriorate, or in the event that management revises its forecasts, an impairment of goodwill may be recognized.

Changes in the carrying amount of goodwill for the six months ended June 30, 2013 were as follows:



	U.S. Neurosurgery			U.S. Instruments			U.S. Extremities			U.S. Spine and Other			International			Total
	(In thousands)
Goodwill, gross	$	94,312		$	57,514		$	60,353		$	56,219		$	25,669		$	294,067
Accumulated impairment losses
Goodwill at December 31, 2012	94,312			57,514			60,353			56,219			25,669			294,067
Tarsus Medical, Inc. acquisition							116									116
Foreign currency translation	(417		)	(255		)	(267		)	(249		)	(114		)	(1,302		)
Balance at June 30, 2013	$	93,895		$	57,259		$	60,202		$	55,970		$	25,555		$	292,881

The components of the Company’s identifiable intangible assets were as follows:



	Weighted Average Life	June 30, 2013							Weighted Average Life	December 31, 2012
	Weighted Average Life	Cost		Accumulated Amortization			Net		Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in thousands)
Completed technology	12 years	$	80,456	$	(41,496	)	$	38,960	12 years	$	75,692	$	(38,402	)	$	37,290
Customer relationships	12 years	146,333		(74,633		)	71,700		12 years	147,690		(70,005		)	77,685
Trademarks/brand names	31 years	33,578		(15,164		)	18,414		31 years	33,807		(15,034		)	18,773
Trademarks/brand names	Indefinite	48,484		—			48,484		Indefinite	48,484		—			48,484
Supplier relationships	27 years	34,721		(8,561		)	26,160		27 years	34,721		(7,817		)	26,904
All other⁽¹⁾	4 years	4,830		(1,664		)	3,166		4 years	4,519		(1,388		)	3,131
		$	348,402	$	(141,518	)	$	206,884		$	344,913	$	(132,646	)	$	212,267


⁽¹⁾	At June 30, 2013 and December 31, 2012, all other included in-process research and development of $2.1 million and $1.7 million, respectively, which was indefinite-lived.

Based on quarter-end exchange rates, annual amortization expense is expected to approximate $19.4 million in 2013, $18.4 million in 2014, $16.6 million in 2015, $14.3 million in 2016 and $12.5 million in 2017. Identifiable intangible assets are initially recorded at fair market value at the time of acquisition using an income or cost approach.

DEBT

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

DEBT

Amended and Restated Senior Credit Agreement

On August 10, 2010, the Company entered into an amended and restated credit agreement with a syndicate of lending banks (the “Senior Credit Facility”). The Company amended the Senior Credit Facility on June 8, 2011, and further amended it on May 11, 2012 and June 21, 2013.

The June 8, 2011 amendment:


i.	increased the revolving credit component from $450 million to $600 million and eliminated the $150 million term loan component that existed under the original amended and restated credit agreement;


ii.	allows the Company to further increase the size of the revolving credit component by an aggregate of $200 million with additional commitments;


iii.	provides the Company with decreased borrowing rates and annual commitment fees, and provides more favorable financial covenants; and


iv.	extended the maturity date from August 10, 2015 to June 8, 2016.

On May 11, 2012, the Company entered into another amendment to the Senior Credit Facility (the “2012 Amendment”). The 2012 Amendment modified certain financial and negative covenants. The 2012 Amendment provides that the Company’s Maximum Consolidated Total Leverage Ratio (a measure of net debt to consolidated EBITDA, in each case as defined in the Senior Credit Facility, as amended) during any consecutive four quarter period should not be greater than 3.75 to 1.00 during any such period ending on December 31, 2013 (instead of March 31, 2012). In addition, when calculating consolidated EBITDA for any period, the 2012 Amendment permits the addition of certain costs and expenses in the calculation of consolidated net income for such period, to the extent deducted in the calculation of consolidated net income.

On June 21, 2013, the Company entered into a second amendment to the Senior Credit Facility (the “2013 Amendment”). The 2013 Amendment modified certain financial and negative covenants and increased the Company’s Maximum Consolidated Total Leverage Ratio (a measure of net debt to consolidated EBITDA, in each case as defined in the Senior Credit Facility, as amended) to 4.25 through June 30, 2014, with a step-down to 4.00 through March 31, 2015, and then with another step-down to 3.75 thereafter. In addition, when calculating consolidated EBITDA for any period, the 2013 Amendment permits the addition of certain costs and expenses in the calculation of consolidated net income for such period, to the extent deducted in the calculation of consolidated net income. The effect of the 2013 Amendment is to increase the ability of the Company to borrow under the Senior Credit Facility during the affected periods. The Company capitalized $1.0 million of incremental financing costs in connection with the 2013 Amendment, which will be amortized through the maturity date of the Senior Credit Facility.

The Senior Credit Facility is collateralized by substantially all of the assets of the Company’s U.S. subsidiaries, excluding intangible assets. The Senior Credit Facility is subject to various financial and negative covenants and at June 30, 2013, the Company was in compliance with all such covenants.

Borrowings under the Senior Credit Facility currently bear interest, at the Company’s option, at a rate equal to (i) the Eurodollar Rate (as defined in the Senior Credit Facility, which definition has not changed) in effect from time to time plus the applicable rate (ranging from 1.00% to 1.75%) or (ii) the highest of (x) the weighted average overnight Federal funds rate, as published by the Federal Reserve Bank of New York, plus 0.5%, (y) the prime lending rate of Bank of America, N.A. or (z) the one-month Eurodollar Rate plus 1.0%. The applicable rates are based on the Company’s consolidated total leverage ratio (defined as the ratio of (a) consolidated funded indebtedness less cash in excess of $40 million that is not subject to any restriction of the use or investment thereof to (b) consolidated EBITDA) at the time of the applicable borrowing.

The Company also pays an annual commitment fee (ranging from 0.15% to 0.30%, based on the Company’s consolidated total leverage ratio) on the daily amount by which the revolving credit facility exceeds the outstanding loans and letters of credit under the credit facility.

At June 30, 2013 and December 31, 2012, there was $341.9 million and $321.9 million outstanding under the Senior Credit Facility at a weighted average interest rate of 2.0% and 1.8%, respectively. At June 30, 2013, there was approximately $258.1 million available for borrowing under the Senior Credit Facility. The fair value of outstanding borrowings under the Senior Credit Facility at June 30, 2013 was approximately $335.9 million. The fair value of the Senior Credit Facility was determined by using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2 of the fair value hierarchy. Level 2 inputs represent inputs that are observable for the asset or liability, either directly or indirectly and are other than active market observable inputs that reflect unadjusted quoted prices for identical assets or liabilities. The Company considers the balance to be long term in nature based on its current intent and ability to repay the borrowing outside of the next twelve-month period.

2016 Convertible Senior Notes

On June 15, 2011, the Company issued $230.0 million aggregate principal amount of its 1.625% Convertible Senior Notes due in 2016 (the “2016 Notes”). The 2016 Notes mature on December 15, 2016, and bear interest at a rate of 1.625% per annum payable semi-annually in arrears on December 15 and June 15 of each year. The portion of the debt proceeds that was classified as equity at the time of the offering was $43.2 million, an equivalent of that amount is being amortized to interest expense using the effective interest method through December 2016. The effective interest rate implicit in the liability component is 5.6%.

At June 30, 2013, the carrying amount of the liability component was $201.4 million, the remaining unamortized discount was $28.6 million, and the principal amount outstanding was $230.0 million. The fair value of the 2016 Notes at June 30, 2013 was approximately $230.1 million. At December 31, 2012, the carrying amount of the liability component was $197.7 million, the remaining unamortized discount was $32.3 million and the principal amount outstanding was $230.0 million. The fair value of the liability of the 2016 Notes was determined using a discounted cash flow model based on current market interest rates available to the Company. These inputs are corroborated by observable market data for similar liabilities and therefore classified within Level 2.

The 2016 Notes are senior, unsecured obligations of the Company, and are convertible into cash and, if applicable, shares of its common stock based on an initial conversion rate, subject to adjustment of 17.4092 shares per $1,000 principal amount of 2016 Notes (which represents an initial conversion price of approximately $57.44 per share). The Company will satisfy any conversion of the 2016 Notes with cash up to the principal amount of the 2016 Notes pursuant to the net share settlement mechanism set forth in the indenture and, with respect to any excess conversion value, with shares of the Company’s common stock. The 2016 Notes are convertible only in the following circumstances: (1) if the closing sale price of the Company’s common stock exceeds 150% of the conversion price during a period as defined in the indenture; (2) if the average trading price per $1,000 principal amount of the 2016 Notes is less than or equal to 98% of the average conversion value of the 2016 Notes during a period as defined in the indenture; (3) at any time on or after June 15, 2016; or (4) if specified corporate transactions occur. The issue price of the 2016 Notes was equal to their face amount, which is also the amount holders are entitled to receive at maturity if the 2016 Notes are not converted. As of June 30, 2013, none of these conditions existed with respect to the 2016 Notes and as a result, the 2016 Notes are classified as long term.

In connection with the issuance of the 2016 Notes, the Company entered into call transactions and warrant transactions, primarily with affiliates of the initial purchasers of such notes (the “hedge participants”). The initial strike price of the call transaction is approximately $57.44 per share, subject to customary anti-dilution adjustments. The initial strike price of the warrant transaction is approximately $70.05 per share, subject to customary anti-dilution adjustments.

Convertible Note Interest

The interest expense components of the Company’s convertible notes are as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
	(In thousands)
2016 Notes:
Amortization of the discount on the liability component	$	1,622	$	1,763	$	3,232	$	3,502
Cash interest related to the contractual interest coupon	813		934		1,631		1,869
Total	$	2,435	$	2,697	$	4,863	$	5,371
2012 Notes:
Amortization of the discount on the liability component	$	—	$	1,206	$	—	$	2,995
Cash interest related to the contractual interest coupon	—		653		—		1,633
Total	$	—	$	1,859	$	—	$	4,628

DERIVATIVE INSTRUMENTS

6 Months Ended

Jun. 30, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS

Interest Rate Hedging

The Company’s interest rate risk relates to U.S. dollar denominated variable LIBOR interest rate borrowings. The Company uses an interest rate swap derivative instrument entered into on August 10, 2010 with an effective date of December 31, 2010 to manage its earnings and cash flow exposure to changes in interest rates by converting a portion of its floating-rate debt into fixed-rate debt beginning on December 31, 2010. This interest rate swap expires on August 10, 2015.

The Company designates this derivative instrument as a cash flow hedge. The Company records the effective portion of any change in the fair value of a derivative instrument designated as a cash flow hedge as unrealized gains or losses in accumulated other comprehensive income (“AOCI”), net of tax, until the hedged item affects earnings, at which point the effective portion of any gain or loss will be reclassified to earnings. If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time.

The Company expects that approximately $1.7 million of pre-tax losses recorded as net in AOCI related to the interest rate hedge could be reclassified to earnings within the next twelve months.

Foreign Currency Hedging

From time to time the Company enters into foreign currency hedge contracts intended to protect the U.S. dollar value of certain forecasted foreign currency denominated transactions. The Company records the effective portion of any change in the fair value of foreign currency cash flow hedges in AOCI, net of tax, until the hedged item affects earnings. Once the related hedged item affects earnings, the Company reclassifies the effective portion of any related unrealized gain or loss on the foreign currency cash flow hedge to earnings. If the hedged forecasted transaction does not occur, or if it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time.

The success of the Company’s hedging program depends, in part, on forecasts of certain activity denominated in euros. The Company may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility. In addition, changes in currency exchange rates related to any unhedged transactions may affect its earnings and cash flows.

Counterparty Credit Risk

The Company manages its concentration of counterparty credit risk on its derivative instruments by limiting acceptable counterparties to a group of major financial institutions with investment grade credit ratings, and by actively monitoring their credit ratings and outstanding positions on an ongoing basis. Therefore, the Company considers the credit risk of the counterparties to be low. Furthermore, none of the Company’s derivative transactions are subject to collateral or other security arrangements, and none contain provisions that depend upon the Company’s credit ratings from any credit rating agency.

Fair Value of Derivative Instruments

The Company has classified all of its derivative instruments within Level 2 of the fair value hierarchy because observable inputs are available for substantially the full term of the derivative instruments. The fair value of the foreign currency forward exchange contracts related to inventory purchases is determined by comparing the forward rate as of the period end and the settlement rate specified in each contract. The fair value of the interest rate swaps was developed using a market approach based on publicly available market yield curves and the terms of the related swap. The Company performs ongoing assessments of counterparty credit risk.

The following table summarizes the fair value and presentation in the condensed consolidated balance sheets for derivatives designated as hedging instruments as of June 30, 2013 and December 31, 2012:



	Fair Value as of					Notional Amount as of
Location on Balance Sheet ⁽¹⁾:	June 30, 2013			December 31, 2012		June 30, 2013		December 31, 2012
	(In thousands)
Derivatives designated as hedges — Assets:
Foreign currency forward contracts — Other current assets	$	(27	)	—		$	1,392
Derivatives designated as hedges — Liabilities:
Interest rate swap — Accrued expenses and other current liabilities ⁽²⁾	1,748			1,888
Interest rate swap — Other liabilities⁽²⁾	1,282			2,238
Total Derivatives designated as hedges — Liabilities	$	3,030		$	4,126


⁽¹⁾	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.


⁽²⁾	At June 30, 2013 and December 31, 2012, the notional amount related to the Company’s sole interest rate swap was $120.0 million and $127.5 million, respectively. In the next twelve months, the Company expects to reduce the notional amount by $15.0 million.

The following presents the effect of derivative instruments designated as cash flow hedges on the accompanying consolidated statements of operations during the three and six months ended June 30, 2013 and 2012:



	Balance in AOCI Beginning of Quarter			Amount of Gain (Loss) Recognized in AOCI- Effective Portion			Amount of Gain (Loss) Reclassified from AOCI into Earnings-Effective Portion			Balance in AOCI End of Quarter			Location in Statements of Operations
	(In thousands)
Three Months Ended June 30, 2013
Forward currency forward contracts	$	—		$	162		$	—		$	162		Costs of goods sold
Interest rate swap	(3,644		)	108			(506		)	(3,030		)	Interest (expense)
	$	(3,644	)	$	270		$	(506	)	$	(2,868	)
Three Months Ended June 30, 2012
Forward currency forward contracts	$	(9	)	$	(338	)	$	(171	)	$	(176	)	Costs of goods sold
Interest rate swap	(4,092		)	(759		)	(477		)	(4,374		)	Interest (expense)
	$	(4,101	)	$	(1,097	)	$	(648	)	$	(4,550	)

	Balance in AOCI Beginning of Year			Amount of Gain (Loss) Recognized in AOCI- Effective Portion			Amount of Gain (Loss) Reclassified from AOCI into Earnings-Effective Portion			Balance in AOCI End of Quarter			Location in Statements of Operations
	(In thousands)
Six Months Ended June 30, 2013
Forward currency forward contracts	$	(34	)	$	162		$	(34	)	$	162		Cost of goods sold
Interest rate swap	(4,125		)	99			(996		)	(3,030		)	Interest (expense)
	$	(4,159	)	$	261		$	(1,030	)	$	(2,868	)
Six Months Ended June 30, 2012
Forward currency forward contracts	$	(216	)	$	(131	)	$	(171	)	$	(176	)	Cost of goods sold
Interest rate swap	(4,092		)	(1,208		)	(926		)	(4,374		)	Interest (expense)
	$	(4,308	)	$	(1,339	)	$	(1,097	)	$	(4,550	)

The Company recognized no gains or losses resulting from ineffectiveness of cash flow hedges during the three and six months ended June 30, 2013 and 2012.

STOCK-BASED COMPENSATION	6 Months Ended
STOCK-BASED COMPENSATION	Jun. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION As of June 30, 2013, the Company had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock unit awards outstanding under three plans, the 2000 Equity Incentive Plan (the “2000 Plan”), the 2001 Equity Incentive Plan (the “2001 Plan”), and the 2003 Equity Incentive Plan (the “2003 Plan,” and collectively, the “Plans”). Stock options issued under the Plans become exercisable over specified periods, generally within four years from the date of grant for officers and directors, and generally expire from six to ten years for directors and certain executive officers. Restricted stock issued under the Plans vests over specified periods, generally three years after the date of grant. Performance stock vesting, issued under the Plans, is subject to service and performance conditions. Stock Options There were 32,468 stock options granted during the six months ended June 30, 2013. As of June 30, 2013, there were approximately $1.8 million of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of approximately one year. Awards of Restricted Stock, Performance Stock and Contract Stock Performance stock, restricted stock and contract stock awards generally have requisite service periods of three years. Performance stock awards are subject to graded vesting conditions and the Company expenses their fair value over the requisite service period. The Company expenses the fair value of restricted stock and contract stock awards on a straight-line basis over the vesting period or requisite service period, whichever is shorter. The Company granted approximately 174,000 restricted stock awards/stock units and 55,000 performance shares during the six months ended June 30, 2013. As of June 30, 2013, there were approximately $16.2 million of total unrecognized compensation costs related to these unvested awards. The Company expects to recognize these costs over a weighted-average period of approximately two years. The Company has no formal policy related to the repurchase of shares for the purpose of satisfying stock-based compensation obligations. The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions. The ESPP is a non-compensatory plan based on its terms.

TREASURY STOCK	6 Months Ended
TREASURY STOCK	Jun. 30, 2013
Treasury Stock Transactions, Excluding Value of Shares Reissued [Abstract]
TREASURY STOCK	TREASURY STOCK On October 23, 2012, the Company's Board of Directors authorized a repurchase of up to $75.0 million of its outstanding common stock through December 2014. The Company has not repurchased any of its outstanding shares of common stock during the three and six month periods ended June 30, 2013 and 2012. As of June 30, 2013, there remained $75.0 million available for repurchases under this authorization.

RETIREMENT BENEFIT PLANS

6 Months Ended

Jun. 30, 2013

Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]

RETIREMENT BENEFIT PLANS

The Company maintains defined benefit pension plans that cover employees in its manufacturing plants located in Andover, United Kingdom (the “UK Plan”) and Tuttlingen, Germany (the “Germany Plan”). The Company closed the Tuttlingen, Germany plant in December 2005. The Company did not terminate the Germany Plan, and the Company remains obligated for the accrued pension benefits related to this plan. Effective March 31, 2011, the Company froze the benefits due to the participants of the UK Plan in their entirety; this curtailment resulted in a $0.3 million reduction in the projected benefit obligations which the Company recorded on that date. The plans cover certain current and former employees.

Net periodic benefit costs for the Company’s defined benefit pension plans included the following amounts:



	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
	(In thousands)
Service cost	$	—		$	6		$	—		$	12
Interest cost	136			161			273			321
Return on plan assets	(100		)	(145		)	(200		)	(289		)
Net period benefit cost	$	36		$	22		$	73		$	44

The Company made $0.4 million of contributions to its defined benefit pension plans during the six months ended June 30, 2013 and 2012.

INCOME TAXES

6 Months Ended

Jun. 30, 2013

Income Tax Disclosure [Abstract]

INCOME TAXES

The following table provides a summary of the Company’s effective tax rate:



	Three Months Ended June 30,
	2013		2012
Reported tax rate	(14.9	)%	26.4	%
	Six Months Ended June 30,
	2013		2012
Reported tax rate	77.9	%	28.1	%

The Company’s effective income tax rates for the three months ended June 30, 2013 and 2012 were (14.9)% and 26.4%, respectively. For the three months ended June 30, 2013, the reduction in the income tax rate compared to the same period in 2012 was primarily the result of a change in the jurisdictional mix of year-to-date worldwide pretax income and the establishment of the Irish research and development credit. During the quarter, the Company was granted an Irish research and development credit for 2011 and 2012, which resulted in a benefit of $0.5 million. The Company also recorded a benefit of $0.8 million for the release of uncertain tax positions due to the expiration of the statute of limitation in certain state jurisdictions, which is offset by an expense of $0.3 million due to additional non-U.S. tax contingency reserves.

The Company's effective income tax rates for the six months ended June 30, 2013 and 2012 were 77.9% and 28.1%, respectively. For the six months ended June 30, 2013, the increase in the income tax rate compared to the same period in 2012 primarily resulted from a change in the jurisdictional mix of year-to-date worldwide pretax income, a reinstatement of the Federal research and development credit of, which resulted in a benefit $0.9 million and the establishment of the Irish research and development credit.

The Company expects its effective income tax rate for the full year to be approximately 4.5% resulting in part from foreign earnings taxed at lower tax rates, the expected release of tax contingency reserves, and the benefit from the Federal research credit. This estimate could be revised in the future as additional information is presented to the Company.

NET INCOME PER SHARE

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

NET INCOME PER SHARE

Basic and diluted net income per share was as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013			2012
	(In thousands, except per share amounts)
Basic net income per share:
Net income (loss)	$	3,440	$	8,514	$	(610	)	$	15,207
Weighted average common shares outstanding	27,873		28,419		27,834			28,382
Basic net income per common share	$	0.12	$	0.30	$	(0.02	)	$	0.54
Diluted net income per share:
Net income (loss)	$	3,440	$	8,514	$	(610	)	$	15,207
Weighted average common shares outstanding — Basic	27,873		28,419		27,834			28,382
Effect of dilutive securities:
Stock options and restricted stock	245		190		—			167
Weighted average common shares for diluted earnings per share	28,118		28,609		27,834			28,549
Diluted net income per common share	$	0.12	$	0.30	$	(0.02	)	$	0.53

At June 30, 2013 and 2012, the Company had 1.7 million of outstanding stock options. The Company also has warrants outstanding relating to its 2016 Notes at June 30, 2013 and 2012. Stock options, restricted stock and warrants are included in the diluted earnings per share calculation using the treasury stock method, unless the effect of including the stock options would be anti-dilutive. For the three months ended June 30, 2013 and 2012, 1.0 million and 1.2 million of anti-dilutive stock options, respectively, were excluded from the diluted earnings per share calculation. As the strike price of the warrants exceeded the Company’s average stock price for the period, the warrants are anti-dilutive and the entire number of warrants was also excluded from the diluted earnings per share calculation. For the six months ended June 30, 2013, all stock options, restricted stock and warrants are excluded in the diluted earnings per share calculation using the treasury stock method because of their anti-dilutive effect.

COMPREHENSIVE (LOSS) INCOME

6 Months Ended

Jun. 30, 2013

Equity [Abstract]

COMPREHENSIVE (LOSS) INCOME

Comprehensive (loss) income was as follows:



	Three Months Ended June 30,					Six Months Ended June 30,
	2013		2012			2013			2012
	(In thousands)
Net (loss) income	$	3,440	$	8,514		$	(610	)	$	15,207
Foreign currency translation adjustment	1,357		(11,005		)	(5,423		)	(4,158		)
Change in unrealized gain on derivatives, net of tax	451		(241		)	747			(136		)
Pension liability adjustment, net of tax	69		2			69			(2		)
Comprehensive (loss) income	$	5,317	$	(2,730	)	$	(5,217	)	$	10,911

Changes in Accumulated Other Comprehensive Income by component between December 31, 2012 and June 30, 2013 are presented in the table below, net of tax:



	Gains and Losses on Cash Flow Hedges			Defined Benefit Pension Items			Foreign Currency Items			Total
	(In thousands)
Beginning balance	$	(2,373	)	$	(1,154	)	$	(1,270	)	$	(4,797	)
Other comprehensive income before reclassifications	160			69			(5,423		)	(5,194		)
Amounts reclassified from accumulated other comprehensive income	(587		)	—			—			(587)
Net current-period other comprehensive income (loss)	747			69			(5,423		)	(4,607		)
Ending balance	$	(1,626	)	$	(1,085	)	$	(6,693	)	$	(9,404	)

The reclassification adjustments out of Accumulated Other Comprehensive (Loss) Income during the three and six months ended June 30, 2013 were as follows:



Three Months Ended June 30, 2013
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statement where Net Income (loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(506	)	Interest (expense)
Foreign currency forwards	—			Cost of goods sold
	(506		)	Total before tax
	218			Tax (expense) or benefit
	$	(288	)	Net of tax



Six Months Ended June 30, 2013
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statement where Net Income (loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(996	)	Interest (expense)
Foreign currency forwards	(34		)	Cost of goods sold
	(1,030		)	Total before tax
	443			Tax (expense) or benefit
	$	(587	)	Net of tax

SEGMENT AND GEOGRAPHIC INFORMATION

6 Months Ended

Jun. 30, 2013

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

The Company internally manages and reports the results of its businesses to its chief operating decision maker through five reportable segments. The five reportable segments are U.S. Neurosurgery, U.S. Instruments, U.S. Extremities, U.S. Spine and Other, and International. The U.S. Neurosurgery segment sells a full line of products specifically for neurosurgery and critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The U.S. Instruments business sells more than 60,000 instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The U.S. Extremities segment includes the U.S. Extremity reconstruction business, which includes such offerings as skin and wound repair, bone and joint fixation, implants in the upper and lower extremities, bone grafts and nerve and tendon repair. The U.S. Spine and Other segment includes (i) the U.S. Spine business, which focuses on spinal fusion, spinal implants, and deformity correction, together with bone graft substitutes and other related medical devices that are used to enhance the repair and regeneration of bone in various types of orthopedic surgical procedures, and (ii) the Private Label business, which sells the Company’s regenerative medicine and other products to strategic partners. The International segment sells similar products to those discussed above, but are managed through the following geographies: (i) Europe, Middle East and Africa, and (ii) Central/South America, Asia-Pacific and Canada. The Corporate and other category includes (i) various legal, finance, executive, and human resource functions, (ii) brand management, (iii) share-based compensation costs, and (iv) costs related to procurement, manufacturing operations and logistics for the Company’s entire organization.

The operating results of the various reportable segments as presented are not comparable to one another because (i) certain operating segments are more dependent than others on corporate functions for unallocated general and administrative and/or operational manufacturing functions, and (ii) the Company does not allocate certain manufacturing costs and general and administrative costs to the operating segment results.

Net sales and profit by reportable segment for the three and six months ended June 30, 2013 and 2012 and three months ended March 31, 2013 and 2012 are as follows:



	Three Months Ended March 31,						Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012			2013			2012
	(In thousands)
Segment Net Sales
U.S. Neurosurgery	$	38,996		$	40,183		$	41,767		$	42,324		$	80,763		$	82,507
U.S. Instruments	36,948			37,994			39,991			41,269			76,939			79,263
U.S. Extremities	31,361			26,587			33,538			32,048			64,899			58,635
U.S. Spine and Other	43,548			44,810			42,962			48,823			86,510			93,633
International	45,799			46,611			47,289			45,706			93,088			92,317
Total revenues	$	196,652		$	196,185		$	205,547		$	210,170		$	402,199		$	406,355
Segment Profit
U.S. Neurosurgery	$	16,904		$	21,156		$	19,786		$	21,890		$	36,690		$	43,046
U.S. Instruments	9,312			10,067			11,206			11,982			20,518			22,049
U.S. Extremities	10,734			9,183			13,225			13,305			23,959			22,488
U.S. Spine and Other	13,183			13,533			12,284			13,862			25,467			27,395
International	12,654			17,465			14,350			13,441			27,004			30,906
Segment profit	62,787			71,404			70,851			74,480			133,638			145,884
Amortization	(3,551		)	(4,720		)	(3,073		)	(4,647)			(6,624)			(9,367)
Corporate and other	(59,280		)	(49,217		)	(59,800		)	(51,812		)	(119,080		)	(101,029		)
Operating (loss) income	$	(44	)	$	17,467		$	7,978		$	18,021		$	7,934		$	35,488

The segment profits for the U.S. Instruments and U.S. Extremities segments, and Corporate and Other for the three and six months ended June 30, 2012 have been revised. The segment profits for the U.S. Instruments and U.S. Extremities segments for the three months ended March 31, 2013 and 2012 have been also revised.

Revenue by major product category consisted of the following:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
	(In thousands)
Orthopedics	$	91,434	$	95,695	$	181,694	$	181,847
Neurosurgery	68,459		67,775		131,644		133,832
Instruments	45,654		46,700		88,861		90,676
Total Revenues	$	205,547	$	210,170	$	402,199	$	406,355

The Company attributes revenues to geographic areas based on the location of the customer. There are certain revenues that the various U.S. segments manage that are generated from non-U.S. customers and therefore are included in Europe and the Rest of World revenues below. Total revenue by major geographic area consisted of the following:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
	(In thousands)
United States	$	157,166	$	163,483	$	307,185	$	312,157
Europe	23,776		22,884		47,393		46,552
Rest of World	24,605		23,803		47,621		47,646
Total Revenues	$	205,547	$	210,170	$	402,199	$	406,355

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In consideration for certain technology, manufacturing, distribution, and selling rights and licenses granted to the Company, the Company has agreed to pay royalties on sales of certain products that we sell. The royalty payments that the Company made under these agreements were not significant for any of the periods presented. The Company is subject to various claims, lawsuits and proceedings in the ordinary course of the Company's business, including claims by current or former employees, distributors and competitors and with respect to its products and product liability claims, lawsuits and proceedings, some of which have been settled by the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material adverse effect on our financial condition. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies. On June 6, 2012, the Company was contacted by the United States Attorney's Office for the District of New Jersey regarding the activities of sales representatives in a single region within our Extremities Reconstruction division. The U.S. Attorney's Office is investigating the activities of three sales representatives, one of whom was a supervisor until terminated by the Company for failure to cooperate with this investigation. The activities at issue pertain to alleged improper billing of products for extremities indications. The Company is cooperating with the United States Attorney's Office on a voluntary basis and is not a subject or target of an investigation at this time. The Company accrues for loss contingencies when it is deemed probable that a loss has been incurred and that loss is estimable. The amounts accrued are based on the full amount of the estimated loss before considering insurance proceeds, and do not include an estimate for legal fees expected to be incurred in connection with the loss contingency. The Company consistently accrues legal fees expected to be incurred in connection with loss contingencies as those fees are incurred by outside counsel as a period cost.

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2013
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS On July 1, 2013, the Company entered into a Lease Agreement with 109 Morgan Lane, LLC (the "Landlord") (the "Lease"). The Lease terminates and replaces the prior lease between the Company and the Landlord dated May 15, 2008, as amended. The Company is leasing approximately 58,011 square feet located at 109 Morgan Lane, Plainsboro, New Jersey (the "Premises") for general office, labs (research & development and/or product development), manufacturing and warehouse purposes. The term of the Lease is 20 years from July 1, 2013 to June 30, 2033 with a 5 year renewal option. The rent for the Premises is $585.9 thousand per year, with monthly rent payments of $48.8 thousand. Additional payments are also required to be made by the Company to the Landlord consisting of $290.1 thousand per year, with monthly payments of $24.2 thousand for taxes and operating expenses as well as other charges. In addition, pursuant to the Lease, the Landlord agreed to pay the Company (i) $40.0 thousand of the total cost to replace the existing roof on the building and (ii) $100.0 thousand of the total cost to replace all of the existing windows in the building.

BUSINESS ACQUISITIONS (Tables) (Tarsus Medical, Inc.)

6 Months Ended

Jun. 30, 2013

Tarsus Medical, Inc.

Business Acquisition [Line Items]

Schedule of Purchase Price Allocation

The following summarizes the final allocation of the purchase price based on fair value of the assets acquired and liabilities assumed:



	Final Purchase Price Allocation
	(Dollars in thousands)
Cash	$	85
Prepaid expenses	13
Intangible assets			Wtd. Avg. Life:
Technology	5,040		10 - 14 years
In-process research and development	340		Indefinite
Deferred tax asset - long term	1,334
Goodwill	116
Total assets acquired	6,928
Accounts payable and other liabilities	111
Deferred tax liability	2,152
Net assets acquired	$	4,665

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule Of Changes In Carrying Amount Of Goodwill

Changes in the carrying amount of goodwill for the six months ended June 30, 2013 were as follows:



	U.S. Neurosurgery			U.S. Instruments			U.S. Extremities			U.S. Spine and Other			International			Total
	(In thousands)
Goodwill, gross	$	94,312		$	57,514		$	60,353		$	56,219		$	25,669		$	294,067
Accumulated impairment losses
Goodwill at December 31, 2012	94,312			57,514			60,353			56,219			25,669			294,067
Tarsus Medical, Inc. acquisition							116									116
Foreign currency translation	(417		)	(255		)	(267		)	(249		)	(114		)	(1,302		)
Balance at June 30, 2013	$	93,895		$	57,259		$	60,202		$	55,970		$	25,555		$	292,881

Components Of Company's Identifiable Intangible Assets

The components of the Company’s identifiable intangible assets were as follows:



	Weighted Average Life	June 30, 2013							Weighted Average Life	December 31, 2012
	Weighted Average Life	Cost		Accumulated Amortization			Net		Weighted Average Life	Cost		Accumulated Amortization			Net
	(Dollars in thousands)
Completed technology	12 years	$	80,456	$	(41,496	)	$	38,960	12 years	$	75,692	$	(38,402	)	$	37,290
Customer relationships	12 years	146,333		(74,633		)	71,700		12 years	147,690		(70,005		)	77,685
Trademarks/brand names	31 years	33,578		(15,164		)	18,414		31 years	33,807		(15,034		)	18,773
Trademarks/brand names	Indefinite	48,484		—			48,484		Indefinite	48,484		—			48,484
Supplier relationships	27 years	34,721		(8,561		)	26,160		27 years	34,721		(7,817		)	26,904
All other⁽¹⁾	4 years	4,830		(1,664		)	3,166		4 years	4,519		(1,388		)	3,131
		$	348,402	$	(141,518	)	$	206,884		$	344,913	$	(132,646	)	$	212,267


⁽¹⁾	At June 30, 2013 and December 31, 2012, all other included in-process research and development of $2.1 million and $1.7 million, respectively, which was indefinite-lived.

DEBT (Tables)

6 Months Ended

Jun. 30, 2013

Debt Disclosure [Abstract]

Components Of Interest Expense

The interest expense components of the Company’s convertible notes are as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
	(In thousands)
2016 Notes:
Amortization of the discount on the liability component	$	1,622	$	1,763	$	3,232	$	3,502
Cash interest related to the contractual interest coupon	813		934		1,631		1,869
Total	$	2,435	$	2,697	$	4,863	$	5,371
2012 Notes:
Amortization of the discount on the liability component	$	—	$	1,206	$	—	$	2,995
Cash interest related to the contractual interest coupon	—		653		—		1,633
Total	$	—	$	1,859	$	—	$	4,628

DERIVATIVE INSTRUMENTS (Tables)

6 Months Ended

Jun. 30, 2013

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Summary Of Fair Value In Balance Sheet For Derivatives Designated As Hedging Instruments



	Fair Value as of					Notional Amount as of
Location on Balance Sheet ⁽¹⁾:	June 30, 2013			December 31, 2012		June 30, 2013		December 31, 2012
	(In thousands)
Derivatives designated as hedges — Assets:
Foreign currency forward contracts — Other current assets	$	(27	)	—		$	1,392
Derivatives designated as hedges — Liabilities:
Interest rate swap — Accrued expenses and other current liabilities ⁽²⁾	1,748			1,888
Interest rate swap — Other liabilities⁽²⁾	1,282			2,238
Total Derivatives designated as hedges — Liabilities	$	3,030		$	4,126


⁽¹⁾	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.


⁽²⁾	At June 30, 2013 and December 31, 2012, the notional amount related to the Company’s sole interest rate swap was $120.0 million and $127.5 million, respectively. In the next twelve months, the Company expects to reduce the notional amount by $15.0 million.

Effect Of Derivative Instruments Designated As Cash Flow Hedges On Statements Of Operations



	Balance in AOCI Beginning of Quarter			Amount of Gain (Loss) Recognized in AOCI- Effective Portion			Amount of Gain (Loss) Reclassified from AOCI into Earnings-Effective Portion			Balance in AOCI End of Quarter			Location in Statements of Operations
	(In thousands)
Three Months Ended June 30, 2013
Forward currency forward contracts	$	—		$	162		$	—		$	162		Costs of goods sold
Interest rate swap	(3,644		)	108			(506		)	(3,030		)	Interest (expense)
	$	(3,644	)	$	270		$	(506	)	$	(2,868	)
Three Months Ended June 30, 2012
Forward currency forward contracts	$	(9	)	$	(338	)	$	(171	)	$	(176	)	Costs of goods sold
Interest rate swap	(4,092		)	(759		)	(477		)	(4,374		)	Interest (expense)
	$	(4,101	)	$	(1,097	)	$	(648	)	$	(4,550	)

	Balance in AOCI Beginning of Year			Amount of Gain (Loss) Recognized in AOCI- Effective Portion			Amount of Gain (Loss) Reclassified from AOCI into Earnings-Effective Portion			Balance in AOCI End of Quarter			Location in Statements of Operations
	(In thousands)
Six Months Ended June 30, 2013
Forward currency forward contracts	$	(34	)	$	162		$	(34	)	$	162		Cost of goods sold
Interest rate swap	(4,125		)	99			(996		)	(3,030		)	Interest (expense)
	$	(4,159	)	$	261		$	(1,030	)	$	(2,868	)
Six Months Ended June 30, 2012
Forward currency forward contracts	$	(216	)	$	(131	)	$	(171	)	$	(176	)	Cost of goods sold
Interest rate swap	(4,092		)	(1,208		)	(926		)	(4,374		)	Interest (expense)
	$	(4,308	)	$	(1,339	)	$	(1,097	)	$	(4,550	)

RETIREMENT BENEFIT PLANS (Tables)

6 Months Ended

Jun. 30, 2013

Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]

Net Periodic Benefit Costs For Defined Benefit Pension Plans

Net periodic benefit costs for the Company’s defined benefit pension plans included the following amounts:



	Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012
	(In thousands)
Service cost	$	—		$	6		$	—		$	12
Interest cost	136			161			273			321
Return on plan assets	(100		)	(145		)	(200		)	(289		)
Net period benefit cost	$	36		$	22		$	73		$	44

INCOME TAXES (Tables)

6 Months Ended

Jun. 30, 2013

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation

The following table provides a summary of the Company’s effective tax rate:



	Three Months Ended June 30,
	2013		2012
Reported tax rate	(14.9	)%	26.4	%
	Six Months Ended June 30,
	2013		2012
Reported tax rate	77.9	%	28.1	%

NET INCOME PER SHARE (Tables)

6 Months Ended

Jun. 30, 2013

Earnings Per Share [Abstract]

Basic And Diluted Net Income Per Share

Basic and diluted net income per share was as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013			2012
	(In thousands, except per share amounts)
Basic net income per share:
Net income (loss)	$	3,440	$	8,514	$	(610	)	$	15,207
Weighted average common shares outstanding	27,873		28,419		27,834			28,382
Basic net income per common share	$	0.12	$	0.30	$	(0.02	)	$	0.54
Diluted net income per share:
Net income (loss)	$	3,440	$	8,514	$	(610	)	$	15,207
Weighted average common shares outstanding — Basic	27,873		28,419		27,834			28,382
Effect of dilutive securities:
Stock options and restricted stock	245		190		—			167
Weighted average common shares for diluted earnings per share	28,118		28,609		27,834			28,549
Diluted net income per common share	$	0.12	$	0.30	$	(0.02	)	$	0.53

COMPREHENSIVE (LOSS) INCOME (Tables)

6 Months Ended

Jun. 30, 2013

Equity [Abstract]

Schedule of Comprehensive (Loss) Income

Comprehensive (loss) income was as follows:



	Three Months Ended June 30,					Six Months Ended June 30,
	2013		2012			2013			2012
	(In thousands)
Net (loss) income	$	3,440	$	8,514		$	(610	)	$	15,207
Foreign currency translation adjustment	1,357		(11,005		)	(5,423		)	(4,158		)
Change in unrealized gain on derivatives, net of tax	451		(241		)	747			(136		)
Pension liability adjustment, net of tax	69		2			69			(2		)
Comprehensive (loss) income	$	5,317	$	(2,730	)	$	(5,217	)	$	10,911

Schedule of Changes in Accumulated Other Comprehensive Income by Component

Changes in Accumulated Other Comprehensive Income by component between December 31, 2012 and June 30, 2013 are presented in the table below, net of tax:



	Gains and Losses on Cash Flow Hedges			Defined Benefit Pension Items			Foreign Currency Items			Total
	(In thousands)
Beginning balance	$	(2,373	)	$	(1,154	)	$	(1,270	)	$	(4,797	)
Other comprehensive income before reclassifications	160			69			(5,423		)	(5,194		)
Amounts reclassified from accumulated other comprehensive income	(587		)	—			—			(587)
Net current-period other comprehensive income (loss)	747			69			(5,423		)	(4,607		)
Ending balance	$	(1,626	)	$	(1,085	)	$	(6,693	)	$	(9,404	)

Reclassification out of Accumulated Other Comprehensive Income (Loss)

The reclassification adjustments out of Accumulated Other Comprehensive (Loss) Income during the three and six months ended June 30, 2013 were as follows:



Three Months Ended June 30, 2013
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statement where Net Income (loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(506	)	Interest (expense)
Foreign currency forwards	—			Cost of goods sold
	(506		)	Total before tax
	218			Tax (expense) or benefit
	$	(288	)	Net of tax



Six Months Ended June 30, 2013
Details about Accumulated Other Comprehensive Income Components	Amount Reclassified from Accumulated Other Comprehensive Income			Affected Line Item in the Statement where Net Income (loss) is Presented
	(In thousands)
Gains and losses on cash flow hedges
Interest rate swap	$	(996	)	Interest (expense)
Foreign currency forwards	(34		)	Cost of goods sold
	(1,030		)	Total before tax
	443			Tax (expense) or benefit
	$	(587	)	Net of tax

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)

6 Months Ended

Jun. 30, 2013

Segment Reporting [Abstract]

Schedule Of Net Sales And Operating Income By Reportable Segment

Net sales and profit by reportable segment for the three and six months ended June 30, 2013 and 2012 and three months ended March 31, 2013 and 2012 are as follows:



	Three Months Ended March 31,						Three Months Ended June 30,						Six Months Ended June 30,
	2013			2012			2013			2012			2013			2012
	(In thousands)
Segment Net Sales
U.S. Neurosurgery	$	38,996		$	40,183		$	41,767		$	42,324		$	80,763		$	82,507
U.S. Instruments	36,948			37,994			39,991			41,269			76,939			79,263
U.S. Extremities	31,361			26,587			33,538			32,048			64,899			58,635
U.S. Spine and Other	43,548			44,810			42,962			48,823			86,510			93,633
International	45,799			46,611			47,289			45,706			93,088			92,317
Total revenues	$	196,652		$	196,185		$	205,547		$	210,170		$	402,199		$	406,355
Segment Profit
U.S. Neurosurgery	$	16,904		$	21,156		$	19,786		$	21,890		$	36,690		$	43,046
U.S. Instruments	9,312			10,067			11,206			11,982			20,518			22,049
U.S. Extremities	10,734			9,183			13,225			13,305			23,959			22,488
U.S. Spine and Other	13,183			13,533			12,284			13,862			25,467			27,395
International	12,654			17,465			14,350			13,441			27,004			30,906
Segment profit	62,787			71,404			70,851			74,480			133,638			145,884
Amortization	(3,551		)	(4,720		)	(3,073		)	(4,647)			(6,624)			(9,367)
Corporate and other	(59,280		)	(49,217		)	(59,800		)	(51,812		)	(119,080		)	(101,029		)
Operating (loss) income	$	(44	)	$	17,467		$	7,978		$	18,021		$	7,934		$	35,488

Revenues By Market Category

Revenue by major product category consisted of the following:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
	(In thousands)
Orthopedics	$	91,434	$	95,695	$	181,694	$	181,847
Neurosurgery	68,459		67,775		131,644		133,832
Instruments	45,654		46,700		88,861		90,676
Total Revenues	$	205,547	$	210,170	$	402,199	$	406,355

Total Revenue By Major Geographic Area

Total revenue by major geographic area consisted of the following:



	Three Months Ended June 30,				Six Months Ended June 30,
	2013		2012		2013		2012
	(In thousands)
United States	$	157,166	$	163,483	$	307,185	$	312,157
Europe	23,776		22,884		47,393		46,552
Rest of World	24,605		23,803		47,621		47,646
Total Revenues	$	205,547	$	210,170	$	402,199	$	406,355

BUSINESS ACQUISITIONS (Additional Information) (Details) (Tarsus Medical, Inc., USD $)	0 Months Ended
	Jan. 24, 2013
Business Acquisition [Line Items]
Business combination, consideration transferred	$ 4,665,000
Payments to acquire business net of cash acquired	2,800,000
Business combination, contingent consideration, liability	1,600,000
Cash Consideration One
Business Acquisition [Line Items]
Business combination, contingent consideration arrangements, range of outcomes, value, low	1,500,000
Fair value inputs, discount rate	4.30%
Cash Consideration Two
Business Acquisition [Line Items]
Business acquisition, additional cash consideration payable upon completion of milestones	$ 11,500,000
Fair value inputs, discount rate	16.50%

BUSINESS ACQUISITIONS (Schedule of Purchase Price Allocation) (Details) (USD $) In Thousands, unless otherwise specified				6 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Jan. 24, 2013 Tarsus Medical, Inc.	Jun. 30, 2013 Tarsus Medical, Inc. Completed Technology Minimum	Jun. 30, 2013 Tarsus Medical, Inc. Completed Technology Maximum
Business Acquisition [Line Items]
Cash			$ 85
Prepaid expenses			13
Technology			5,040
In-process research and development			340
Deferred tax asset - long term			1,334
Goodwill	292,881	294,067	116
Total assets acquired			6,928
Accounts payable and other liabilities			111
Deferred tax liability			2,152
Net assets acquired			$ 4,665
Weighted average useful life				10 years	14 years

INVENTORIES (Inventory, Net) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Inventory, Net [Abstract]
Finished goods	$ 118,464	$ 102,401
Work-in process	44,771	39,944
Raw materials	32,222	29,461
Inventories, net	$ 195,457	$ 171,806

GOODWILL AND OTHER INTANGIBLE ASSETS (Additional Information) (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 292,881,000	$ 294,067,000
Annual amortization expense expected to approximate in 2013	19,400,000
Annual amortization expense expected to approximate in 2014	18,400,000
Annual amortization expense expected to approximate in 2015	16,600,000
Annual amortization expense expected to approximate in 2016	14,300,000
Annual amortization expense expected to approximate in 2017	$ 12,500,000

GOODWILL AND OTHER INTANGIBLE ASSETS (Schedule of Changes in Carrying Amount of Goodwill) (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended		6 Months Ended		6 Months Ended		6 Months Ended		6 Months Ended		6 Months Ended			6 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2013 Tarsus Medical, Inc.	Jan. 24, 2013 Tarsus Medical, Inc.	Jun. 30, 2013 U.S. Neurosurgery	Dec. 31, 2012 U.S. Neurosurgery	Jun. 30, 2013 U.S. Instruments	Dec. 31, 2012 U.S. Instruments	Jun. 30, 2013 U.S. Extremities	Dec. 31, 2012 U.S. Extremities	Jun. 30, 2013 U.S. Extremities Tarsus Medical, Inc.	Jun. 30, 2013 U.S. Spine And Other	Dec. 31, 2012 U.S. Spine And Other	Jun. 30, 2013 International	Dec. 31, 2012 International
Goodwill [Line Items]
Goodwill, gross		$ 294,067				$ 94,312		$ 57,514		$ 60,353			$ 56,219		$ 25,669
Accumulated impairment losses
Goodwill [Roll Forward]
Beginning period, December 31, 2012	294,067			116	94,312		57,514		60,353			56,219		25,669
Goodwill acquired during period			116								116
Foreign currency translation	(1,302)				(417)		(255)		(267)			(249)		(114)
Ending period, June 30, 2013	$ 292,881			$ 116	$ 93,895		$ 57,259		$ 60,202			$ 55,970		$ 25,555

GOODWILL AND OTHER INTANGIBLE ASSETS (Components of Company's Identifiable Intangible Assets) (Details) (USD $)
In Thousands, unless otherwise specified

6 Months Ended

12 Months Ended

Jun. 30, 2013

Dec. 31, 2012

Acquired Finite-Lived Intangible Assets [Line Items]

Cost

$ 348,402

$ 344,913

Accumulated Amortization

(141,518)

(132,646)

Net

206,884

212,267

Completed technology

Acquired Finite-Lived Intangible Assets [Line Items]

Weighted Average Life

12 years

Cost

80,456

75,692

Accumulated Amortization

(41,496)

(38,402)

Net

38,960

37,290

Customer relationships

Acquired Finite-Lived Intangible Assets [Line Items]

Weighted Average Life

12 years

Cost

146,333

147,690

Accumulated Amortization

(74,633)

(70,005)

Net

71,700

77,685

Trademarks/brand names

Acquired Finite-Lived Intangible Assets [Line Items]

Weighted Average Life

31 years

Cost

33,578

33,807

Accumulated Amortization

(15,164)

(15,034)

Net

18,414

18,773

Trademarks/brand names indefinite

Acquired Finite-Lived Intangible Assets [Line Items]

Cost

48,484

Accumulated Amortization

Net

48,484

Supplier relationships

Acquired Finite-Lived Intangible Assets [Line Items]

Weighted Average Life

27 years

Cost

34,721

Accumulated Amortization

(8,561)

(7,817)

Net

26,160

26,904

All other

Acquired Finite-Lived Intangible Assets [Line Items]

Weighted Average Life

4 years

^[1]

4 years

^[1]

Cost

4,830

^[1]

4,519

^[1]

Accumulated Amortization

(1,664)

^[1]

(1,388)

^[1]

Net

$ 3,166

^[1]

$ 3,131

^[1]

[1]	At June 30, 2013 and December 31, 2012, all other included in-process research and development of $2.1 million and $1.7 million, respectively, which was indefinite-lived.

GOODWILL AND OTHER INTANGIBLE ASSETS (Components of Company's Identifiable Intangible Assets) (Parenthetical) (Details) (In-Process Research And Development, USD $) In Millions, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
In-Process Research And Development
Indefinite-lived Intangible Assets [Line Items]
Indefinite lived in-process research and development	$ 2.1	$ 1.7

DEBT (Additional Information) (Detail) (USD $)					6 Months Ended											3 Months Ended				6 Months Ended
DEBT (Additional Information) (Detail) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2013 Revolving Credit Facility	Dec. 31, 2012 Revolving Credit Facility	Jun. 30, 2013 Revolving Credit Facility Option (ii), (x)	Jun. 30, 2013 Revolving Credit Facility Option (ii), (z)	Jun. 30, 2013 Revolving Credit Facility Minimum	Jun. 30, 2013 Revolving Credit Facility Minimum Option (i)	Jun. 30, 2013 Revolving Credit Facility Maximum	Jun. 30, 2013 Revolving Credit Facility Maximum Option (i)	Jun. 30, 2013 Revolving Credit Facility August 2010 Amendment	Jun. 30, 2013 Revolving Credit Facility June 2011 Amendment	Jun. 30, 2013 Revolving Credit Facility June 2011 Amendment Minimum	Jun. 30, 2013 Revolving Credit Facility June 2011 Amendment Maximum	Jun. 30, 2013 Revolving Credit Facility May 2012 Amendment Maximum	Jun. 30, 2013 Revolving Credit Facility June 2013 Amendment	Jun. 30, 2013 Revolving Credit Facility June 2013 Amendment Maximum	Jun. 30, 2013 Revolving Credit Facility June 2013 Amendment Leverage Ratio after March 31, 2015	Jun. 30, 2013 Revolving Credit Facility June 2013 Amendment Maximum Levarage Ratio July 01, 2014 through March 31.2015	Jun. 30, 2013 2016 Convertible Senior Notes	Dec. 31, 2012 2016 Convertible Senior Notes	Jun. 15, 2011 2016 Convertible Senior Notes
Debt Instrument [Line Items]
Senior credit facility, maximum borrowing capacity													$ 450,000,000	$ 600,000,000
Reallocated term loan												150,000,000
Additional commitments												200,000,000
Line of credit facility, expiration date											Aug. 10, 2015	Jun. 08, 2016
Leverage ratio															3.75		4.25	3.75	4.00
Debt issuance costs																1,000,000
Interest rates available to the Company at its option					0.50%	1.00%		1.00%		1.75%
Cash balance threshold above which excess amount is not subject to any restriction of use or investment			40,000,000
Line of credit, commitment fee percentage							0.15%		0.30%
Line of credit facility outstanding			341,900,000	321,900,000
Weighted average interest rate on debt			2.00%	1.80%
Available borrowings under senior secured revolving credit facility			258,100,000
Fair value of outstanding borrowings			335,900,000																	230,100,000
Principal amount outstanding																				230,000,000	230,000,000	230,000,000
Interest rate on debt																						1.625%
Portion of the debt proceeds that was classified as equity at the time of the offering																						43,200,000
Effective interest rate implicit in the liability component																				5.60%
Carrying amount of liability	201,375,000	197,672,000																		201,400,000	197,700,000
Unamortized discount																				28,600,000	32,300,000
Common stock based on initial conversion rate ratio (in shares)																				17.4092
Principal amount to be considered for conversion purpose																				1,000
Initial conversion price, per share																				$ 57.44
Maximum selling price of company's common stock																				150.00%
Principal amount of notes per average trading price																				$ 1,000
Maximum average conversion value of the Notes																				98.00%
Earliest conversion date																				June 15, 2016
Strike price of the call transaction (in dollars per share)																				$ 57.44
Strike price of warrant transactions (in dollars per share)																				$ 70.05

DEBT (Components of Interest Expense) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
2016 Convertible Senior Notes
Debt Instrument [Line Items]
Amortization of the discount on the liability component	$ 1,622	$ 1,763	$ 3,232	$ 3,502
Cash interest related to the contractual interest coupon	813	934	1,631	1,869
Total	2,435	2,697	4,863	5,371
2012 Senior Convertible Notes
Debt Instrument [Line Items]
Amortization of the discount on the liability component	0	1,206	0	2,995
Cash interest related to the contractual interest coupon	0	653	0	1,633
Total	$ 0	$ 1,859	$ 0	$ 4,628

DERIVATIVE INSTRUMENTS (Additional Information) (Detail) (USD $) In Millions, unless otherwise specified	6 Months Ended
	Jun. 30, 2013
Derivative [Line Items]
Interest rate swap expiration date	August 10, 2015
Interest Rate Swap
Derivative [Line Items]
Pretax losses expected to be reclassified from AOCI in next 12 months	$ 1.7

DERIVATIVE INSTRUMENTS (Summary of Fair Value in Balance Sheet for Derivatives Designated Hedging Instruments) (Detail) (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2013

Dec. 31, 2012

Derivative Instruments and Hedging Activities Disclosure [Line Items]

Fair value of derivative liabilities

$ 3,030

^[1]

$ 4,126

^[1]

Foreign Exchange Contract | Other current assets

Derivative Instruments and Hedging Activities Disclosure [Line Items]

Fair value of derivative assets

(27)

^[1]

Notional amount derivative instruments

1,392

^[1]

Interest Rate Swap

Derivative Instruments and Hedging Activities Disclosure [Line Items]

Notional amount derivative instruments

120,000

127,500

Interest Rate Swap | Accrued expenses and other current liabilities

Derivative Instruments and Hedging Activities Disclosure [Line Items]

Fair value of derivative liabilities

1,748

^[1],[2]

1,888

^[1],[2]

Interest Rate Swap | Other liabilities

Derivative Instruments and Hedging Activities Disclosure [Line Items]

Fair value of derivative liabilities

$ 1,282

^[1],[2]

$ 2,238

^[1],[2]

[1]	The Company classifies derivative assets and liabilities as current based on the cash flows expected to be incurred within the following 12 months.
[2]	At June 30, 2013 and December 31, 2012, the notional amount related to the Company’s sole interest rate swap was $120.0 million and $127.5 million, respectively. In the next twelve months, the Company expects to reduce the notional amount by $15.0 million.

DERIVATIVE INSTRUMENTS (Summary of Fair Value in Balance Sheet for Derivatives Designated Hedging Instruments) (Parenthetical) (Detail) (Interest Rate Swap, USD $)	6 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosure [Line Items]
Notional amount derivative instruments	$ 120,000,000	$ 127,500,000
Reduction in notional amount of interest rate derivatives in next twelve months	$ 15,000,000

DERIVATIVE INSTRUMENTS (Effect of Derivative Instruments Designated Cash Flow Hedges on Statements of Operations) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Derivative Instruments, Gain (Loss) [Line Items]
Balance in AOCI Beginning of Period	$ (3,644)	$ (4,101)	$ (4,159)	$ (4,308)
Amount of Gain (Loss) Recognized in AOCI- Effective Portion	270	(1,097)	261	(1,339)
Amount of Gain (Loss) Reclassified from AOCI into Earnings-Effective Portion	(506)	(648)	(1,030)	(1,097)
Balance in AOCI End of Period	(2,868)	(4,550)	(2,868)	(4,550)
Cost of goods sold \| Foreign Currency Forward Contracts
Derivative Instruments, Gain (Loss) [Line Items]
Balance in AOCI Beginning of Period	0	(9)	(34)	(216)
Amount of Gain (Loss) Recognized in AOCI- Effective Portion	162	(338)	162	(131)
Amount of Gain (Loss) Reclassified from AOCI into Earnings-Effective Portion	0	(171)	(34)	(171)
Balance in AOCI End of Period	162	(176)	162	(176)
Interest (expense) \| Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Balance in AOCI Beginning of Period	(3,644)	(4,092)	(4,125)	(4,092)
Amount of Gain (Loss) Recognized in AOCI- Effective Portion	108	(759)	99	(1,208)
Amount of Gain (Loss) Reclassified from AOCI into Earnings-Effective Portion	(506)	(477)	(996)	(926)
Balance in AOCI End of Period	$ (3,030)	$ (4,374)	$ (3,030)	$ (4,374)

STOCK-BASED COMPENSATION (Additional Information) (Detail) (USD $) In Millions, except Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	32,468
Requisite service periods of awards, in years	3 years
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period, in years	4 years
Total unrecognized compensation costs	$ 1.8
Weighted-average period for cost recognition, in years	1 year
Restricted stock awards/stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable, vesting period, in years	3 years
Total unrecognized compensation costs	$ 16.2
Weighted-average period for cost recognition, in years	2 years
Awards granted during period	174,000
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted during period	55,000
Minimum \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable for directors, expiration period, in years	6 years
Maximum \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable for directors, expiration period, in years	10 years

TREASURY STOCK (Additional Information) (Detail) (USD $)	6 Months Ended	0 Months Ended
	Jun. 30, 2013	Oct. 23, 2012 October 2012 Authorization
Accelerated Share Repurchases [Line Items]
Stock repurchase program, authorized amount		$ 75,000,000
Amount available for share repurchase under this latest authorization	$ 75,000,000

RETIREMENT BENEFIT PLANS (Additional Information) (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended	6 Months Ended
	Mar. 31, 2011	Jun. 30, 2013	Jun. 30, 2012
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Reduction in projected benefit obligations	$ 0.3
Total contributions made by the Company		$ 0.4	$ 0.4

RETIREMENT BENEFIT PLANS (Net Periodic Benefit Costs for Defined Benefit Pension Plans) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Service cost	$ 0	$ 6	$ 0	$ 12
Interest cost	136	161	273	321
Return on plan assets	(100)	(145)	(200)	(289)
Net period benefit cost	$ 36	$ 22	$ 73	$ 44

INCOME TAXES (Additional Information) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Income Tax Examination [Line Items]
Reported tax rate	(14.90%)	26.40%	77.90%	28.10%
Effective tax rate estimate	4.50%
State and Local Jurisdiction
Income Tax Examination [Line Items]
Income tax examination, increase (decrease) in liability from prior year	$ (0.8)		$ (0.8)
Foreign Tax Authority
Income Tax Examination [Line Items]
Income tax reconciliation, tax credits, research	0.5
Income tax examination, increase (decrease) in liability from prior year	0.3		0.3
Internal Revenue Service (IRS)
Income Tax Examination [Line Items]
Income tax reconciliation, tax credits, research			$ 0.9

NET INCOME PER SHARE (Additional Information) (Detail) In Millions, unless otherwise specified	3 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options, shares outstanding (in shares)	1.7	1.7
Stock Compensation Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from computation as their effect would be anti-dilutive	1.0	1.2

NET INCOME PER SHARE (Basic and Diluted Net Income Per Share) (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Basic net income per share:
Net income (loss)	$ 3,440	$ 8,514	$ (610)	$ 15,207
Weighted average common shares outstanding (in shares)	27,873	28,419	27,834	28,382
Basic net income per common share (in dollars per share)	$ 0.12	$ 0.30	$ (0.02)	$ 0.54
Diluted net income per share:
Net income (loss)	$ 3,440	$ 8,514	$ (610)	$ 15,207
Weighted average common shares outstanding (in shares)	27,873	28,419	27,834	28,382
Effect of dilutive securities:
Stock options and restricted stock (in shares)	245	190	0	167
Weighted average common shares for diluted earnings per share (in shares)	28,118	28,609	27,834	28,549
Diluted net income per common share (in dollars per share)	$ 0.12	$ 0.30	$ (0.02)	$ 0.53

COMPREHENSIVE (LOSS) INCOME (Schedule of Comprehensive Loss Income) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Equity [Abstract]
Net (loss) income	$ 3,440	$ 8,514	$ (610)	$ 15,207
Foreign currency translation adjustment	1,357	(11,005)	(5,423)	(4,158)
Change in unrealized gain on derivatives, net of tax	451	(241)	747	(136)
Pension liability adjustment, net of tax	69	2	69	(2)
Comprehensive (loss) income	$ 5,317	$ (2,730)	$ (5,217)	$ 10,911

COMPREHENSIVE (LOSS) INCOME (Schedule of Changes in Accumulated Other Comprehensive Income by Component (Details) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	$ (4,797)
Other comprehensive income before reclassifications	(5,194)
Amounts reclassified from accumulated other comprehensive income	(587)
Net current-period other comprehensive income (loss)	(4,607)
Ending balance	(9,404)
Gains and Losses on Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(2,373)
Other comprehensive income before reclassifications	160
Amounts reclassified from accumulated other comprehensive income	(587)
Net current-period other comprehensive income (loss)	747
Ending balance	(1,626)
Defined Benefit Pension Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(1,154)
Other comprehensive income before reclassifications	69
Amounts reclassified from accumulated other comprehensive income	0
Net current-period other comprehensive income (loss)	69
Ending balance	(1,085)
Foreign Currency Items
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning balance	(1,270)
Other comprehensive income before reclassifications	(5,423)
Amounts reclassified from accumulated other comprehensive income	0
Net current-period other comprehensive income (loss)	(5,423)
Ending balance	$ (6,693)

COMPREHENSIVE (LOSS) INCOME (Reclassification Adjustment from AOCI) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)	$ (4,965)	$ (7,103)	$ (9,765)	$ (15,032)
Cost of goods sold	(83,068)	(78,274)	(163,336)	(152,949)
Total before tax	2,995	11,569	(2,760)	21,162
Tax (expense) or benefit	445	(3,055)	2,150	(5,955)
Net income (loss)	3,440	8,514	(610)	15,207
Reclassification out of Accumulated Other Comprehensive Income \| Gains and Losses on Cash Flow Hedges
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	(506)		1,030
Tax (expense) or benefit	218		443
Net income (loss)	(288)		(587)
Reclassification out of Accumulated Other Comprehensive Income \| Gains and Losses on Cash Flow Hedges \| Interest Rate Swap
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest (expense)	(506)		(996)
Reclassification out of Accumulated Other Comprehensive Income \| Gains and Losses on Cash Flow Hedges \| Foreign Currency Forwards
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Cost of goods sold	$ 0		$ (34)

SEGMENT AND GEOGRAPHIC INFORMATION (Net Sales and Profit by Reportable Segment) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended				6 Months Ended
	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2012	Mar. 31, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenue from External Customer [Line Items]
Segment Net Sales	$ 205,547	$ 196,652	$ 210,170	$ 196,185	$ 402,199	$ 406,355
Segment Profit	70,851	62,787	74,480	71,404	133,638	145,884
Amortization	(3,073)	(3,551)	(4,647)	(4,720)	(6,624)	(9,367)
Corporate and other	(59,800)	(59,280)	(51,812)	(49,217)	(119,080)	(101,029)
Operating income	7,978	(44)	18,021	17,467	7,934	35,488
U.S. Neurosurgery
Revenue from External Customer [Line Items]
Segment Net Sales	41,767	38,996	42,324	40,183	80,763	82,507
Segment Profit	19,786	16,904	21,890	21,156	36,690	43,046
U.S. Instruments
Revenue from External Customer [Line Items]
Segment Net Sales	39,991	36,948	41,269	37,994	76,939	79,263
Segment Profit	11,206	9,312	11,982	10,067	20,518	22,049
U.S. Extremities
Revenue from External Customer [Line Items]
Segment Net Sales	33,538	31,361	32,048	26,587	64,899	58,635
Segment Profit	13,225	10,734	13,305	9,183	23,959	22,488
U.S. Spine And Other
Revenue from External Customer [Line Items]
Segment Net Sales	42,962	43,548	48,823	44,810	86,510	93,633
Segment Profit	12,284	13,183	13,862	13,533	25,467	27,395
International
Revenue from External Customer [Line Items]
Segment Net Sales	47,289	45,799	45,706	46,611	93,088	92,317
Segment Profit	$ 14,350	$ 12,654	$ 13,441	$ 17,465	$ 27,004	$ 30,906

SEGMENT AND GEOGRAPHIC INFORMATION (Revenue by Major Product Category) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended				6 Months Ended
	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2012	Mar. 31, 2012	Jun. 30, 2013	Jun. 30, 2012
Revenue from External Customer [Line Items]
Total Revenues	$ 205,547	$ 196,652	$ 210,170	$ 196,185	$ 402,199	$ 406,355
Orthopedics
Revenue from External Customer [Line Items]
Total Revenues	91,434		95,695		181,694	181,847
Neurosurgery
Revenue from External Customer [Line Items]
Total Revenues	68,459		67,775		131,644	133,832
Instruments
Revenue from External Customer [Line Items]
Total Revenues	$ 45,654		$ 46,700		$ 88,861	$ 90,676

SEGMENT AND GEOGRAPHIC INFORMATION (Total Revenue by Major Geographic Area) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended				6 Months Ended
	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2012	Mar. 31, 2012	Jun. 30, 2013	Jun. 30, 2012
Segment Reporting Information [Line Items]
Total Revenues	$ 205,547	$ 196,652	$ 210,170	$ 196,185	$ 402,199	$ 406,355
United States
Segment Reporting Information [Line Items]
Total Revenues	157,166		163,483		307,185	312,157
Europe
Segment Reporting Information [Line Items]
Total Revenues	23,776		22,884		47,393	46,552
Rest of World
Segment Reporting Information [Line Items]
Total Revenues	$ 24,605		$ 23,803		$ 47,621	$ 47,646

SUBSEQUENT EVENTS (Details) (Subsequent Event, USD $)	0 Months Ended
SUBSEQUENT EVENTS (Details) (Subsequent Event, USD $)	Jul. 01, 2013 sqft
Subsequent Event [Line Items]
Area of leased property	58,011
Operating lease contract term	20 years
Operating lease renewal term	5 years
Roof replacement cost	$ 40,000
Window replacement cost	100,000
One month period
Subsequent Event [Line Items]
Operating leases, rent expense, minimum rentals	48,800
Operating leases, additional rent	24,200
12 month period
Subsequent Event [Line Items]
Operating leases, rent expense, minimum rentals	585,900
Operating leases, additional rent	$ 290,100

INVENTORIES Inventory Narrative (Details) (USD $) In Millions, unless otherwise specified	Jun. 30, 2013
Inventory Disclosure [Abstract]
Inventory, medical device tax	$ 4.6

SEGMENT AND GEOGRAPHIC INFORMATION (Additional Information) (Detail)	6 Months Ended
	Jun. 30, 2013 Segment
Segment Reporting [Abstract]
Number of reportable segments	5

GOODWILL AND OTHER INTANGIBLE ASSETS (Reporting units at risk) (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Reporting Unit [Line Items]
Goodwill	$ 292,881	$ 294,067
U.S. Spine
Reporting Unit [Line Items]
Goodwill	46,800
Private Label
Reporting Unit [Line Items]
Goodwill	$ 8,900

INCOME TAXES (Summary of Effective Tax Rate) (Detail)	3 Months Ended		6 Months Ended
INCOME TAXES (Summary of Effective Tax Rate) (Detail)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Income Tax Disclosure [Abstract]
Reported tax rate	(14.90%)	26.40%	77.90%	28.10%